Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Saja Almaaitah

Rheumatology Grand Rapids, MI Medical Doctor

NPI 1073033759 CMS profile 4167417

3271 Clear Vista Ct Ne, Grand Rapids, MI 49525

Open in the dashboard

General payments

$7,597

464 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Saja Almaaitah of Grand Rapids, MI is reported in the CMS Open Payments database as having received $7,597 across 464 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,402 91
2024 General $2,838 163
2023 General $2,635 159
2022 General $722 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Saja Almaaitah
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Saja Almaaitah were reported at $1,402. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Saja Almaaitah Rheumatology median Middle half National median
2019 $0 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $722 $627 $125–$2,303 $149
2023 $2,635 $741 $145–$2,524 $160
2024 $2,838 $830 $166–$2,660 $164
2025 $1,402 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $2,089 117 payments
  2. Amgen Inc. $2,005 156 payments
  3. Janssen Biotech, Inc. $915 77 payments
  4. AstraZeneca Pharmaceuticals LP $672 25 payments
  5. Novartis Pharmaceuticals Corporation $328 14 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $266 9 payments
  7. Pfizer Inc. $212 12 payments
  8. Fresenius Kabi USA, LLC $195 8 payments
  9. Lilly USA, LLC $180 8 payments
  10. Alexion Pharmaceuticals, Inc. $161 3 payments
  11. Other $575 35 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,364 460 payments
  2. Education $233 4 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $1,603 86 payments
  2. Enbrel $866 82 payments
  3. TAVNEOS $782 56 payments
  4. Otezla $771 74 payments
  5. TREMFYA $770 66 payments
  6. SAPHNELO $672 25 payments
  7. SKYRIZI $407 25 payments
  8. SIMPONI ARIA $336 31 payments
  9. COSENTYX $240 10 payments
  10. XELJANZ $212 12 payments
  11. Other $2,451 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,813

Median for Rheumatology: 1,511

Drug cost

$1,864,726

Median for Rheumatology: $1,139,948

Branded share of claims

33.5%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 85 $643,941
Enbrel Sureclick Etanercept Brand 57 $408,357
Enbrel Etanercept Brand 28 $248,451
Rinvoq Upadacitinib Brand 18 $108,888
Otezla Apremilast Brand 11 $92,511
Humira Adalimumab Brand 13 $85,314
Xeljanz Xr Tofacitinib Citrate Brand 12 $70,381
Kineret Anakinra Brand 12 $65,720
Actemra Tocilizumab Brand 18 $52,399
Actemra Actpen Tocilizumab Brand 17 $35,970

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$11,617

Medicare's payments for the services billed

Medicare patients

91

Average age 68

Services billed

146

68 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 59%
Depression 30%
Osteoporosis 30%
Diabetes 22%
Chronic kidney disease 16%
Heart failure 15%
Ischemic heart disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $466
$466 — —
RINVOQ
  • AbbVie, Inc. $308
$308 18 —
TREMFYA
  • Janssen Biotech, Inc. $267
$267 — —
TAVNEOS
  • Amgen Inc. $240
$240 — —
SKYRIZI
  • AbbVie, Inc. $230
$230 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

464 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record